<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02190006</url>
  </required_header>
  <id_info>
    <org_study_id>sub 4</org_study_id>
    <nct_id>NCT02190006</nct_id>
  </id_info>
  <brief_title>Comparison Between the Role of Follicular Output Rate and Preovulatory Count in the Prediction of Pregnancy in Women With Polycystic Ovarian Syndrome Undergoing Intra Cytoplasmic Sperm Injection (ICSI)</brief_title>
  <official_title>Comparison Between the Role of Follicular Output Rate and Preovulatory Count in the Prediction of Pregnancy in Women With Polycystic Ovarian Syndrome Undergoing Intra Cytoplasmic Sperm Injection (ICSI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study is observational, we are observing data from routine measurements during IVF/ICSI.&#xD;
      Our study does not assess IVF/ICSI as an intervention, we are evaluating the role of FSI and&#xD;
      preovulatory count which are calculated by observing routine measurements during the IVF/ICSI&#xD;
      procedure.&#xD;
&#xD;
      300 women with polycystic ovarian syndrome (PCOS) who are decided to be treated with ICSI.&#xD;
      will be subjected to full history taking and clinical examination. On the second day of&#xD;
      menstruation serum FSH, LH, Prolactin and Oestradiol will be assessed and the antral&#xD;
      follicular count (AFC) will be assessed using a vaginal ultrasound scan. AFC will be defined&#xD;
      as the number of follicles measuring 3-10mm.&#xD;
&#xD;
      All patients will have standard pituitary down-regulation followed by follicle stimulating&#xD;
      hormone (FSH) stimulation until the day of Human chorionic gonadotrophin (HCG)&#xD;
      administration.&#xD;
&#xD;
      On the day of HCG administration, ovarian ultrasound scan will be performed using a&#xD;
      transvaginal probe and the Preovulatory follicle count (PC) will be assessed, (PFC) is&#xD;
      defined as number of follicles measuring≥16mm. Follicular output rate (FORT) will be&#xD;
      calculated as: (FSI =PFC*10000/AFC*Total dose of FSH).&#xD;
&#xD;
      FORT correlation to pregnancy will be compared to that of the preovulatory count number&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study is observational, we are observing data from routine measurements during IVF/ICSI.&#xD;
      Our study does not assess IVF/ICSI as an intervention, we are evaluating the role of FSI and&#xD;
      preovulatory count which are calculated by observing routine measurements during the IVF/ICSI&#xD;
      procedure.&#xD;
&#xD;
      All women fulfilling the inclusion criteria will be invited to participate in the study. A&#xD;
      written informed consent will be taken and only women signing the consent will be included in&#xD;
      the study. Patients included in the study will be subjected to full history taking and&#xD;
      clinical examination including general, abdominal and gynecological examination. This will be&#xD;
      followed by a vaginal ultrasound scan to assess uterus, ovaries and any pelvic masses.&#xD;
&#xD;
      All women will go through the usual IVF/ICSI procedure explained below, our aim is to observe&#xD;
      the antral follicle count, the pre-ovulatory count, and calculate the FORT.&#xD;
&#xD;
      On the second day of menstruation serum FSH, LH, Prolactin and Oestradiol will be assessed&#xD;
      and the antral follicular count (AFC) will be assessed using a vaginal ultrasound scan. AFC&#xD;
      will be defined as the number of follicles measuring 3-10mm.&#xD;
&#xD;
      All patients will have standard pituitary down-regulation protocol with GnRHa (Triptorelin&#xD;
      0.1mg, Decapeptyl® Ferring, Germany) day 7 after ovulation of previous cycle or on day 21 of&#xD;
      the oral contraceptive cycles. GnRHa will be continued for 2 weeks. FSH (Fostimon ®IBSA)&#xD;
      150-300 IU/day will be administered until the day of HCG administration.&#xD;
&#xD;
      On the day of HCG administration, ovarian ultrasound scan will be performed using a&#xD;
      transvaginal probe and the Preovulatory follicle count (PC) will be assessed, (PFC) is&#xD;
      defined as number of follicles measuring≥16mm. FORT will be calculated as: (PFC) * 100/AFC.&#xD;
&#xD;
      The procedure will be cancelled if less than 3 follicles 16-20 mm in size are present 12 days&#xD;
      after starting FSH despite doses reaching 450 IU. The cycle will be also cancelled if there&#xD;
      is risk of ovarian hyperstimulation like massive ovarian enlargement or serum estradiol&#xD;
      exceeds 3000pg/L Transvaginal oocyte retrieval will be performed 34-36 h after the&#xD;
      administration of HCG. Oocytes will be fertilized either via IVF or ICSI based on the&#xD;
      couple's history. Fertilization will be assessed 16-18 h after IVF or ICSI. Embryo transfers&#xD;
      will be performed 3 days after oocyte retrieval. No more than three embryos per patient will&#xD;
      be transferred; vaginal tablets containing progesterone (Prontogest® IBSA) administered 400&#xD;
      mg/day as luteal support from the day of the oocyte retrieval. Pregnancy will be defined as&#xD;
      the appearance of an intrauterine gestational sac by vaginal ultrasound 5 weeks after embryo&#xD;
      transfer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy</measure>
    <time_frame>5 weeks after embryo transfer</time_frame>
    <description>FORT values will be classified into 3 categories: low, medium and high. The proportion of women achieving a clinical pregnancy will be compared among the 3 groups. Correlation of FORT with clinical pregnancy will be compared with the correlation of preovulatory count with pregnancy using a regression analysis. Clinical pregnancy will be defined as the presence of an intra-uterine gestational sac detected by ultrasound scanning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of embryos</measure>
    <time_frame>3 days after embryo transfer</time_frame>
    <description>Correlation between FORT and the number of embryos will be compared to the correlation of preovulatory count and the number of embryos using regression analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of embryos</measure>
    <time_frame>3 days after ovum pick up</time_frame>
    <description>The correlation between FORT and the quality of embryos will be compared with the correlation of preovulatory count and the quality of embryos using regression analysis.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Polycystic Ovarian Syndrome</condition>
  <condition>Subfertility</condition>
  <condition>ICSI</condition>
  <arm_group>
    <arm_group_label>Polycystic ovarian syndrome</arm_group_label>
    <description>Women with polycystic ovarian syndrome undergoing ICSI</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        300 women with Polycystic ovarian syndrome who are already decided to be treated with ICSI&#xD;
        will be recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PCOS diagnosed using the Rotterdam criteria&#xD;
&#xD;
          -  Age 20-40 years&#xD;
&#xD;
          -  Both ovaries are present&#xD;
&#xD;
          -  Day 2 FSH &lt;10 mIU/L&#xD;
&#xD;
          -  Day 2 Estradiol&lt;50 pg/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other causes of subfertility&#xD;
&#xD;
          -  Abnormalities affecting the uterine cavity&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Allergy to gonadotrophins&#xD;
&#xD;
          -  Cancelled cycles during the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbdelGany MA Hassan, MRCOG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbdelGany MA Hassan, MRCOG, MD</last_name>
    <phone>00201017801604</phone>
    <email>abdelgany2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AbdelGany MA Hassan, MRCOG, MD</last_name>
      <phone>00217801604</phone>
      <email>abdelgany2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>AbdelGany MM Hassan, MRCOG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed MM Kotb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dar AlTeb subfertility centre</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AbdelGany MA Hassan, MRCOG, MD</last_name>
      <phone>00217801604</phone>
      <email>abdelgany2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mohamed MM Kotb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>AbdelGany MA Hassan, MRCOG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed MA AwadAllah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: A prospective randomized trial. J Hum Reprod Sci. 2012 Sep;5(3):262-5. doi: 10.4103/0974-1208.106338.</citation>
    <PMID>23531705</PMID>
  </reference>
  <reference>
    <citation>Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. doi: 10.1093/humrep/deh098.</citation>
    <PMID>14688154</PMID>
  </reference>
  <reference>
    <citation>Kamath MS, George K. Letrozole or clomiphene citrate as first line for anovulatory infertility: a debate. Reprod Biol Endocrinol. 2011 Jun 21;9:86. doi: 10.1186/1477-7827-9-86.</citation>
    <PMID>21693034</PMID>
  </reference>
  <reference>
    <citation>Zhang N, Hao CF, Zhuang LL, Liu XY, Gu HF, Liu S, Chen ZJ. Prediction of IVF/ICSI outcome based on the follicular output rate. Reprod Biomed Online. 2013 Aug;27(2):147-53. doi: 10.1016/j.rbmo.2013.04.012. Epub 2013 May 4.</citation>
    <PMID>23768619</PMID>
  </reference>
  <reference>
    <citation>de Carvalho BR, Rosa e Silva AC, Rosa e Silva JC, dos Reis RM, Ferriani RA, Silva de Sa MF. Ovarian reserve evaluation: state of the art. J Assist Reprod Genet. 2008 Jul;25(7):311-22. doi: 10.1007/s10815-008-9241-2. Epub 2008 Aug 5.</citation>
    <PMID>18679790</PMID>
  </reference>
  <reference>
    <citation>Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril. 2009 Mar;91(3):705-14. doi: 10.1016/j.fertnstert.2007.12.013. Epub 2008 Mar 5.</citation>
    <PMID>18321493</PMID>
  </reference>
  <reference>
    <citation>Melo MA, Garrido N, Alvarez C, Bellver J, Meseguer M, Pellicer A, Remohi J. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertil Steril. 2009 Jan;91(1):148-56. doi: 10.1016/j.fertnstert.2007.11.042. Epub 2008 May 2.</citation>
    <PMID>18455166</PMID>
  </reference>
  <reference>
    <citation>Genro VK, Grynberg M, Scheffer JB, Roux I, Frydman R, Fanchin R. Serum anti-Mullerian hormone levels are negatively related to Follicular Output RaTe (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation. Hum Reprod. 2011 Mar;26(3):671-7. doi: 10.1093/humrep/deq361. Epub 2010 Dec 21.</citation>
    <PMID>21177311</PMID>
  </reference>
  <reference>
    <citation>Gallot V, Berwanger da Silva AL, Genro V, Grynberg M, Frydman N, Fanchin R. Antral follicle responsiveness to follicle-stimulating hormone administration assessed by the Follicular Output RaTe (FORT) may predict in vitro fertilization-embryo transfer outcome. Hum Reprod. 2012 Apr;27(4):1066-72. doi: 10.1093/humrep/der479. Epub 2012 Jan 24.</citation>
    <PMID>22279090</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>July 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2014</study_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>AbdelGany Hassan</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>Polycystic ovarian syndrome</keyword>
  <keyword>Follicle output rate</keyword>
  <keyword>preovulatory count</keyword>
  <keyword>ICSI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02190006
org study id: sub 4
nct id: NCT02190006
lead sponsor: 
has dmc: Yes
Our study is observational, we are observing data from routine measurements during IVF/ICSI.
      Our study does not assess IVF/ICSI as an intervention, we are evaluating the role of FSI and
      preovulatory count which are calculated by observing routine measurements during the IVF/ICSI
      procedure.

      300 women with polycystic ovarian syndrome (PCOS) who are decided to be treated with ICSI.
      will be subjected to full history taking and clinical examination. On the second day of
      menstruation serum FSH, LH, Prolactin and Oestradiol will be assessed and the antral
      follicular count (AFC) will be assessed using a vaginal ultrasound scan. AFC will be defined
      as the number of follicles measuring 3-10mm.

      All patients will have standard pituitary down-regulation followed by follicle stimulating
      hormone (FSH) stimulation until the day of Human chorionic gonadotrophin (HCG)
      administration.

      On the day of HCG administration, ovarian ultrasound scan will be performed using a
      transvaginal probe and the Preovulatory follicle count (PC) will be assessed, (PFC) is
      defined as number of follicles measuring≥16mm. Follicular output rate (FORT) will be
      calculated as: (FSI =PFC*10000/AFC*Total dose of FSH).

      FORT correlation to pregnancy will be compared to that of the preovulatory count number
Our study is observational, we are observing data from routine measurements during IVF/ICSI.
      Our study does not assess IVF/ICSI as an intervention, we are evaluating the role of FSI and
      preovulatory count which are calculated by observing routine measurements during the IVF/ICSI
      procedure.

      All women fulfilling the inclusion criteria will be invited to participate in the study. A
      written informed consent will be taken and only women signing the consent will be included in
      the study. Patients included in the study will be subjected to full history taking and
      clinical examination including general, abdominal and gynecological examination. This will be
      followed by a vaginal ultrasound scan to assess uterus, ovaries and any pelvic masses.

      All women will go through the usual IVF/ICSI procedure explained below, our aim is to observe
      the antral follicle count, the pre-ovulatory count, and calculate the FORT.

      On the second day of menstruation serum FSH, LH, Prolactin and Oestradiol will be assessed
      and the antral follicular count (AFC) will be assessed using a vaginal ultrasound scan. AFC
      will be defined as the number of follicles measuring 3-10mm.

      All patients will have standard pituitary down-regulation protocol with GnRHa (Triptorelin
      0.1mg, Decapeptyl® Ferring, Germany) day 7 after ovulation of previous cycle or on day 21 of
      the oral contraceptive cycles. GnRHa will be continued for 2 weeks. FSH (Fostimon ®IBSA)
      150-300 IU/day will be administered until the day of HCG administration.

      On the day of HCG administration, ovarian ultrasound scan will be performed using a
      transvaginal probe and the Preovulatory follicle count (PC) will be assessed, (PFC) is
      defined as number of follicles measuring≥16mm. FORT will be calculated as: (PFC) * 100/AFC.

      The procedure will be cancelled if less than 3 follicles 16-20 mm in size are present 12 days
      after starting FSH despite doses reaching 450 IU. The cycle will be also cancelled if there
      is risk of ovarian hyperstimulation like massive ovarian enlargement or serum estradiol
      exceeds 3000pg/L Transvaginal oocyte retrieval will be performed 34-36 h after the
      administration of HCG. Oocytes will be fertilized either via IVF or ICSI based on the
      couple's history. Fertilization will be assessed 16-18 h after IVF or ICSI. Embryo transfers
      will be performed 3 days after oocyte retrieval. No more than three embryos per patient will
      be transferred; vaginal tablets containing progesterone (Prontogest® IBSA) administered 400
      mg/day as luteal support from the day of the oocyte retrieval. Pregnancy will be defined as
      the appearance of an intrauterine gestational sac by vaginal ultrasound 5 weeks after embryo
      transfer.
observational model: Cohort
time perspective: Prospective
measure: clinical pregnancy
time frame: 5 weeks after embryo transfer
description: FORT values will be classified into 3 categories: low, medium and high. The proportion of women achieving a clinical pregnancy will be compared among the 3 groups. Correlation of FORT with clinical pregnancy will be compared with the correlation of preovulatory count with pregnancy using a regression analysis. Clinical pregnancy will be defined as the presence of an intra-uterine gestational sac detected by ultrasound scanning.
measure: Number of embryos
time frame: 3 days after embryo transfer
description: Correlation between FORT and the number of embryos will be compared to the correlation of preovulatory count and the number of embryos using regression analysis.
measure: Quality of embryos
time frame: 3 days after ovum pick up
description: The correlation between FORT and the quality of embryos will be compared with the correlation of preovulatory count and the quality of embryos using regression analysis.
arm group label: Polycystic ovarian syndrome
description: Women with polycystic ovarian syndrome undergoing ICSI
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: Female
minimum age: 20 Years
maximum age: 40 Years
healthy volunteers: No
last name: AbdelGany MA Hassan, MRCOG, MD
role: Principal Investigator
affiliation: Cairo University
last name: AbdelGany MA Hassan, MRCOG, MD
phone: 00201017801604
email: abdelgany2@gmail.com
facility: 
status: Recruiting
contact: 
investigator: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
investigator: 
investigator: 
country: Egypt
citation: Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: A prospective randomized trial. J Hum Reprod Sci. 2012 Sep;5(3):262-5. doi: 10.4103/0974-1208.106338.
PMID: 23531705
citation: Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. doi: 10.1093/humrep/deh098.
PMID: 14688154
citation: Kamath MS, George K. Letrozole or clomiphene citrate as first line for anovulatory infertility: a debate. Reprod Biol Endocrinol. 2011 Jun 21;9:86. doi: 10.1186/1477-7827-9-86.
PMID: 21693034
citation: Zhang N, Hao CF, Zhuang LL, Liu XY, Gu HF, Liu S, Chen ZJ. Prediction of IVF/ICSI outcome based on the follicular output rate. Reprod Biomed Online. 2013 Aug;27(2):147-53. doi: 10.1016/j.rbmo.2013.04.012. Epub 2013 May 4.
PMID: 23768619
citation: de Carvalho BR, Rosa e Silva AC, Rosa e Silva JC, dos Reis RM, Ferriani RA, Silva de Sa MF. Ovarian reserve evaluation: state of the art. J Assist Reprod Genet. 2008 Jul;25(7):311-22. doi: 10.1007/s10815-008-9241-2. Epub 2008 Aug 5.
PMID: 18679790
citation: Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril. 2009 Mar;91(3):705-14. doi: 10.1016/j.fertnstert.2007.12.013. Epub 2008 Mar 5.
PMID: 18321493
citation: Melo MA, Garrido N, Alvarez C, Bellver J, Meseguer M, Pellicer A, Remohi J. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertil Steril. 2009 Jan;91(1):148-56. doi: 10.1016/j.fertnstert.2007.11.042. Epub 2008 May 2.
PMID: 18455166
citation: Genro VK, Grynberg M, Scheffer JB, Roux I, Frydman R, Fanchin R. Serum anti-Mullerian hormone levels are negatively related to Follicular Output RaTe (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation. Hum Reprod. 2011 Mar;26(3):671-7. doi: 10.1093/humrep/deq361. Epub 2010 Dec 21.
PMID: 21177311
citation: Gallot V, Berwanger da Silva AL, Genro V, Grynberg M, Frydman N, Fanchin R. Antral follicle responsiveness to follicle-stimulating hormone administration assessed by the Follicular Output RaTe (FORT) may predict in vitro fertilization-embryo transfer outcome. Hum Reprod. 2012 Apr;27(4):1066-72. doi: 10.1093/humrep/der479. Epub 2012 Jan 24.
PMID: 22279090
responsible party type: Principal Investigator
investigator affiliation: Cairo University
investigator full name: AbdelGany Hassan
investigator title: Lecturer
mesh term: Polycystic Ovary Syndrome
mesh term: Infertility
mesh term: Syndrome